<SEC-DOCUMENT>0001104659-25-004466.txt : 20250117
<SEC-HEADER>0001104659-25-004466.hdr.sgml : 20250117
<ACCEPTANCE-DATETIME>20250117160530
ACCESSION NUMBER:		0001104659-25-004466
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250117

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cytosorbents Corp
		CENTRAL INDEX KEY:			0001175151
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				980373793
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-81910
		FILM NUMBER:		25538689

	BUSINESS ADDRESS:	
		STREET 1:		305 COLLEGE ROAD EAST
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540
		BUSINESS PHONE:		973-329-8885

	MAIL ADDRESS:	
		STREET 1:		305 COLLEGE ROAD EAST
		CITY:			PRINCETON
		STATE:			NJ
		ZIP:			08540

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MedaSorb Technologies CORP
		DATE OF NAME CHANGE:	20060807

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GILDER ENTERPRISES INC
		DATE OF NAME CHANGE:	20020611

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SATTERFIELD THOMAS A JR
		CENTRAL INDEX KEY:			0001132317
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	MAIL ADDRESS:	
		STREET 1:		2609 CALDWELL MILL LN
		CITY:			BIRMINGHAM
		STATE:			AL
		ZIP:			35243
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13G</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: SATTERFIELD THOMAS A JR -->
          <cik>0001132317</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock, par value $0.001 per share</securitiesClassTitle>
      <eventDateRequiresFilingThisStatement>01/13/2025</eventDateRequiresFilingThisStatement>
      <issuerInfo>
        <issuerCik>0001175151</issuerCik>
        <issuerName>CytoSorbents Corporation</issuerName>
        <issuerCusip>23283X206</issuerCusip>
        <issuerPrincipalExecutiveOfficeAddress>
          <com:street1>305 College Road East</com:street1>
          <com:city>Princeton</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>08540</com:zipCode>
        </issuerPrincipalExecutiveOfficeAddress>
      </issuerInfo>
      <designateRulesPursuantThisScheduleFiled>
        <designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
      </designateRulesPursuantThisScheduleFiled>
    </coverPageHeader>
    <coverPageHeaderReportingPersonDetails>


      <reportingPersonName>Thomas A. Satterfield, Jr.</reportingPersonName>
      <citizenshipOrOrganization>X1</citizenshipOrOrganization>
      <reportingPersonBeneficiallyOwnedNumberOfShares>
        <soleVotingPower>550310.00</soleVotingPower>
        <sharedVotingPower>3448557.00</sharedVotingPower>
        <soleDispositivePower>550310.00</soleDispositivePower>
        <sharedDispositivePower>3448557.00</sharedDispositivePower>
      </reportingPersonBeneficiallyOwnedNumberOfShares>
      <reportingPersonBeneficiallyOwnedAggregateNumberOfShares>3998867.00</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
      <aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
      <classPercent>6.56</classPercent>
      <typeOfReportingPerson>IN</typeOfReportingPerson>
      <comments>Percentage of class based on (i) 54,679,569 shares of common stock of the issuer outstanding as of November 5, 2024, as reported by the issuer on its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024 and (ii) 6,250,000 shares being issued from the Rights Offering per the Current Report on Form 8-K filed on January 13, 2025. This assumes the exercise of the 131,578 warrants issued in December 2023, 585,479 Class A warrants, and 585,479 Class B warrants beneficially owned by the Reporting Person.</comments>
    </coverPageHeaderReportingPersonDetails>
    <items>
      <item1>
        <issuerName>CytoSorbents Corporation</issuerName>
        <issuerPrincipalExecutiveOfficeAddress>305 College Road East Princeton, NJ 08540</issuerPrincipalExecutiveOfficeAddress>
      </item1>
      <item2>
        <filingPersonName>Thomas A. Satterfield, Jr.</filingPersonName>
        <principalBusinessOfficeOrResidenceAddress>Thomas A. Satterfield, Jr.
15 Colley Cove Drive
Gulf Breeze, Florida 32561</principalBusinessOfficeOrResidenceAddress>
        <citizenship>Incorporated by reference from Item 4 of the Cover Page.</citizenship>
      </item2>
      <item3>
        <notApplicableFlag>Y</notApplicableFlag>
      </item3>
      <item4>
        <amountBeneficiallyOwned>Incorporated by reference from Item 9 of the Cover Page.</amountBeneficiallyOwned>
        <classPercent>Incorporated by reference from Item 11 of the Cover Page.</classPercent>
        <numberOfSharesPersonHas>
          <solePowerOrDirectToVote>Incorporated by reference from Item 5 of the Cover Page.</solePowerOrDirectToVote>
          <sharedPowerOrDirectToVote>Incorporated by reference from Item 6 of the Cover Page.</sharedPowerOrDirectToVote>
          <solePowerOrDirectToDispose>Incorporated by reference from Item 7 of the Cover Page.</solePowerOrDirectToDispose>
          <sharedPowerOrDirectToDispose>Incorporated by reference from Item 8 of the Cover Page.</sharedPowerOrDirectToDispose>
        </numberOfSharesPersonHas>
      </item4>
      <item5>
        <notApplicableFlag>Y</notApplicableFlag>
      </item5>
      <item6>
        <notApplicableFlag>N</notApplicableFlag>
        <ownershipMoreThan5PercentOnBehalfOfAnotherPerson>With respect to the beneficial ownership report for Thomas A. Satterfield, Jr., 51,888 shares of Common Stock, 11,888 shares of Common Stock issuable upon exercise of Class A Warrants, and 11,888 shares of Common Stock issuable upon exercise of Class B Warrants are held jointly with Mr. Satterfield's spouse, Rebecca S. Satterfield;

12,972 shares of Common Stock, 2,972 shares of Common Stock issuable upon exercise of Class A Warrants, and 2,972 shares of Common Stock issuable upon exercise of Class B Warrants are held directly by Mr. Satterfield's spouse, Rebecca S. Satterfield;

464,731 shares of Common Stock, 39,473 shares of Common Stock issuable upon exercise of Warrants, 118,879 shares of Common Stock issuable upon exercise of Class A Warrants, and 118,879 shares of Common Stock issuable upon exercise of Class B Warrants are held by Tomsat Investment &amp; Trading Co., Inc, a corporation wholly owned by Mr. Satterfield and of which he serves as President;

928,318 shares of Common Stock, 92,105 shares of Common Stock issuable upon exercise of Warrants, 178,318 shares of Common Stock issuable upon exercise of Class A Warrants, and 178,318 shares of Common Stock issuable upon exercise of Class B Warrants are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield; and

878,318 shares of Common Stock, 178,318 shares of Common Stock issuable upon exercise of Class A Warrants, and 178,318 shares of Common Stock issuable upon exercise of Class B Warrants shares are held by Caldwell Mill Opportunity Fund, LLC which fund is managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
      </item6>
      <item7>
        <notApplicableFlag>Y</notApplicableFlag>
      </item7>
      <item8>
        <notApplicableFlag>Y</notApplicableFlag>
      </item8>
      <item9>
        <notApplicableFlag>Y</notApplicableFlag>
      </item9>
      <item10>
        <notApplicableFlag>N</notApplicableFlag>
        <certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.</certifications>
      </item10>
    </items>
    <signatureInformation>
      <reportingPersonName>Thomas A. Satterfield, Jr.</reportingPersonName>
      <signatureDetails>
        <signature>/s/ Thomas A. Satterfield, Jr.</signature>
        <title>Thomas A. Satterfield, Jr.</title>
        <date>01/17/2025</date>
      </signatureDetails>
    </signatureInformation>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
